Tumor Infiltrating Lymphocyte Data Signal Promise for New Options to Treat Advanced Melanoma
Source: Targeted Oncology, November 2022
In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.
Tumor infiltrating lymphocyte (TIL) therapy is an immune-oncology (IO) strategy that has been studied for over 2 decades in advanced melanoma, according to Ryan J. Sullivan, MD. Until recently, data around TILs have not been comparable with IO therapies already approved for the treatment of melanoma.
In prior research conducted by the National Cancer Institute (NCI), good responses were achieved in patients who were able to receive TILs. The reality, however, was that most patients with advanced disease and poor prognosis did not survive long enough for the TIL growing and harvesting process to reach completion.